Analogue-Based Drug Discovery III.:
Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Somerset
John Wiley & Sons, Incorporated
2012
|
Ausgabe: | 1st ed |
Schlagworte: | |
Zusammenfassung: | Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and -- together with the previous volumes -- constitutes the first systematic approach to drug analogue development |
Beschreibung: | Description based on publisher supplied metadata and other sources |
Beschreibung: | 1 online resource (435 pages) |
ISBN: | 9783527651108 9783527330737 |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV044050030 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 170217s2012 |||| o||u| ||||||eng d | ||
020 | |a 9783527651108 |9 978-3-527-65110-8 | ||
020 | |a 9783527330737 |c Print |9 978-3-527-33073-7 | ||
035 | |a (ZDB-30-PAD)EBC1123660 | ||
035 | |a (ZDB-89-EBL)EBL1123660 | ||
035 | |a (ZDB-38-EBR)ebr10662582 | ||
035 | |a (OCoLC)826637765 | ||
035 | |a (DE-599)BVBBV044050030 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
082 | 0 | |a 615.19 | |
100 | 1 | |a Fischer, Janos |e Verfasser |4 aut | |
245 | 1 | 0 | |a Analogue-Based Drug Discovery III. |
250 | |a 1st ed | ||
264 | 1 | |a Somerset |b John Wiley & Sons, Incorporated |c 2012 | |
264 | 4 | |c © 2010 | |
300 | |a 1 online resource (435 pages) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
500 | |a Description based on publisher supplied metadata and other sources | ||
520 | |a Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and -- together with the previous volumes -- constitutes the first systematic approach to drug analogue development | ||
650 | 4 | |a Chemistry, Pharmaceutical -- Methods | |
650 | 4 | |a Drug development | |
650 | 4 | |a Drug discovery | |
650 | 4 | |a Technology, pharmaceutical -- Methods | |
700 | 1 | |a Ganellin, C. Robin |e Sonstige |4 oth | |
700 | 1 | |a Rotella, David P. |e Sonstige |4 oth | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Fischer, Janos |t Analogue-Based Drug Discovery III |
912 | |a ZDB-30-PAD | ||
999 | |a oai:aleph.bib-bvb.de:BVB01-029456875 |
Datensatz im Suchindex
_version_ | 1804177067081728000 |
---|---|
any_adam_object | |
author | Fischer, Janos |
author_facet | Fischer, Janos |
author_role | aut |
author_sort | Fischer, Janos |
author_variant | j f jf |
building | Verbundindex |
bvnumber | BV044050030 |
collection | ZDB-30-PAD |
ctrlnum | (ZDB-30-PAD)EBC1123660 (ZDB-89-EBL)EBL1123660 (ZDB-38-EBR)ebr10662582 (OCoLC)826637765 (DE-599)BVBBV044050030 |
dewey-full | 615.19 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 615 - Pharmacology and therapeutics |
dewey-raw | 615.19 |
dewey-search | 615.19 |
dewey-sort | 3615.19 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
edition | 1st ed |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02227nmm a2200445zc 4500</leader><controlfield tag="001">BV044050030</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170217s2012 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527651108</subfield><subfield code="9">978-3-527-65110-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527330737</subfield><subfield code="c">Print</subfield><subfield code="9">978-3-527-33073-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC1123660</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL1123660</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-38-EBR)ebr10662582</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)826637765</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044050030</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fischer, Janos</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Analogue-Based Drug Discovery III.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Somerset</subfield><subfield code="b">John Wiley & Sons, Incorporated</subfield><subfield code="c">2012</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (435 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and -- together with the previous volumes -- constitutes the first systematic approach to drug analogue development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemistry, Pharmaceutical -- Methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug discovery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Technology, pharmaceutical -- Methods</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ganellin, C. Robin</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rotella, David P.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Fischer, Janos</subfield><subfield code="t">Analogue-Based Drug Discovery III</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PAD</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029456875</subfield></datafield></record></collection> |
id | DE-604.BV044050030 |
illustrated | Not Illustrated |
indexdate | 2024-07-10T07:42:11Z |
institution | BVB |
isbn | 9783527651108 9783527330737 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029456875 |
oclc_num | 826637765 |
open_access_boolean | |
physical | 1 online resource (435 pages) |
psigel | ZDB-30-PAD |
publishDate | 2012 |
publishDateSearch | 2012 |
publishDateSort | 2012 |
publisher | John Wiley & Sons, Incorporated |
record_format | marc |
spelling | Fischer, Janos Verfasser aut Analogue-Based Drug Discovery III. 1st ed Somerset John Wiley & Sons, Incorporated 2012 © 2010 1 online resource (435 pages) txt rdacontent c rdamedia cr rdacarrier Description based on publisher supplied metadata and other sources Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and -- together with the previous volumes -- constitutes the first systematic approach to drug analogue development Chemistry, Pharmaceutical -- Methods Drug development Drug discovery Technology, pharmaceutical -- Methods Ganellin, C. Robin Sonstige oth Rotella, David P. Sonstige oth Erscheint auch als Druck-Ausgabe Fischer, Janos Analogue-Based Drug Discovery III |
spellingShingle | Fischer, Janos Analogue-Based Drug Discovery III. Chemistry, Pharmaceutical -- Methods Drug development Drug discovery Technology, pharmaceutical -- Methods |
title | Analogue-Based Drug Discovery III. |
title_auth | Analogue-Based Drug Discovery III. |
title_exact_search | Analogue-Based Drug Discovery III. |
title_full | Analogue-Based Drug Discovery III. |
title_fullStr | Analogue-Based Drug Discovery III. |
title_full_unstemmed | Analogue-Based Drug Discovery III. |
title_short | Analogue-Based Drug Discovery III. |
title_sort | analogue based drug discovery iii |
topic | Chemistry, Pharmaceutical -- Methods Drug development Drug discovery Technology, pharmaceutical -- Methods |
topic_facet | Chemistry, Pharmaceutical -- Methods Drug development Drug discovery Technology, pharmaceutical -- Methods |
work_keys_str_mv | AT fischerjanos analoguebaseddrugdiscoveryiii AT ganellincrobin analoguebaseddrugdiscoveryiii AT rotelladavidp analoguebaseddrugdiscoveryiii |